|
(V1613) |
Dysbindin is a novel cardiac binding partner of Myozap that activates RhoA-SRF mediated hypertrophy in cardiomyocytes |
| |
|
D. Frank, A. Rangrez, A. Bernt, R. Poyanmehr, N. Frey (Kiel) |
|
|
Diskussion |
|
(V1614) |
TRAF molecules control cardiomyocyte proliferation in zebrafish |
| |
|
J. Seeger, S. Zwerenz, E. Patzel, I. Berger, S. Just, W. Rottbauer (Ulm) |
|
|
Diskussion |
|
(V1615) |
Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage |
| |
|
M. Völkers, M. Konstandin, M. A. Sussman (Heidelberg; San Diego, US) |
|
|
Diskussion |
|
(V1616) |
Human cardiomyocytes are protected from titin aggregation-induced stiffening by small heat-shock proteins |
| |
|
S. Kötter, A. Unger, N. Hamdani, W. Linke (Bochum) |
|
|
Diskussion |
|
(V1617) |
Characterization of cTnI-R170G/W - new mutations in TNNI3 associated with restrictive cardiomyopathy |
| |
|
D. Cimiotti, A. Kostareva, N. Smolina, A. Mügge, K. Jaquet (Bochum; Stockholm, SE) |
|
|
Diskussion |
|
(V1618) |
The role of the α2 catalytic isoform of the Na+/K+-ATPase in the failing heart |
| |
|
W. Reuter, N. Kirschmer, S. Frantz, O. Ritter, A. Burr, N. R. Correll, J.D. Molkentin, P. Eder-Negrin (Würzburg; Cincinnati, US) |
|
|
Diskussion |